These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 31683254)

  • 1. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
    Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
    Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an EQ-5D Value Set for India Using an Extended Design (DEVINE) Study: The Indian 5-Level Version EQ-5D Value Set.
    Jyani G; Sharma A; Prinja S; Kar SS; Trivedi M; Patro BK; Goyal A; Purba FD; Finch AP; Rajsekar K; Raman S; Stolk E; Kaur M
    Value Health; 2022 Jul; 25(7):1218-1226. PubMed ID: 35779943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EQ-5D-5L Valuation study in Thailand.
    Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L.
    Hobbins A; Barry L; Kelleher D; Shah K; Devlin N; Goni JMR; O'Neill C
    Pharmacoeconomics; 2018 Nov; 36(11):1345-1353. PubMed ID: 30051267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Indonesian EQ-5D-5L Value Set.
    Purba FD; Hunfeld JAM; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Ramos-Goñi JM; Passchier J; Busschbach JJV
    Pharmacoeconomics; 2017 Nov; 35(11):1153-1165. PubMed ID: 28695543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing health-related quality of life among the Indian population: a protocol for the Development of an EQ-5D Value set for India using an Extended design (DEVINE) Study.
    Jyani G; Prinja S; Kar SS; Trivedi M; Patro B; Purba F; Pala S; Raman S; Sharma A; Jain S; Kaur M
    BMJ Open; 2020 Nov; 10(11):e039517. PubMed ID: 33444194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valuation of the EQ-5D-5L in Taiwan.
    Lin HW; Li CI; Lin FJ; Chang JY; Gau CS; Luo N; Pickard AS; Ramos Goñi JM; Tang CH; Hsu CN
    PLoS One; 2018; 13(12):e0209344. PubMed ID: 30586400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
    Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
    Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An EQ-5D-5L Value Set for Vietnam.
    Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
    Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The EQ-5D-5L Valuation Study in Egypt.
    Al Shabasy S; Abbassi M; Finch A; Roudijk B; Baines D; Farid S
    Pharmacoeconomics; 2022 Apr; 40(4):433-447. PubMed ID: 34786590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A national survey of Iranian general population to estimate a value set for the EQ-5D-5L.
    Afshari S; Daroudi R; Goudarzi R; Mahboub-Ahari A; Yaseri M; Sari AA; Ameri H; Bahariniya S; Oliaei-Manesh A; Kalavani K; Zare Z; Hasannezhad E; Mirzaei M; Amiri Z
    Qual Life Res; 2023 Jul; 32(7):2079-2087. PubMed ID: 36897530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach.
    Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O
    Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
    Ludwig K; von der Schulenburg JG; Greiner W
    Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for Unobservable Preference Heterogeneity and Evaluating Alternative Anchoring Approaches to Estimate Country-Specific EQ-5D-Y Value Sets: A Case Study Using Spanish Preference Data.
    Ramos-Goñi JM; Oppe M; Estévez-Carrillo A; Rivero-Arias O;
    Value Health; 2022 May; 25(5):835-843. PubMed ID: 35500952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuation of EQ-5D-5L in the Kingdom of Saudi Arabia: A National Representative Study.
    Al-Jedai A; Almudaiheem H; Al-Salamah T; Aldosari M; Almutairi AR; Almogbel Y; AlRuthia Y; Althemery AU; Alluhidan M; Roudijk B; Purba FD; Awad N; O'jeil R
    Value Health; 2024 May; 27(5):552-561. PubMed ID: 38342365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EQ-5D-5L Valuation for the Malaysian Population.
    Shafie AA; Vasan Thakumar A; Lim CJ; Luo N; Rand-Hendriksen K; Md Yusof FA
    Pharmacoeconomics; 2019 May; 37(5):715-725. PubMed ID: 30535779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
    Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
    Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol.
    Yang F; Katumba KR; Roudijk B; Yang Z; Revill P; Griffin S; Ochanda PN; Lamorde M; Greco G; Seeley J; Sculpher M
    Pharmacoeconomics; 2022 Mar; 40(3):309-321. PubMed ID: 34841471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.